Capricor Therapeutics (NASDAQ:CAPR) CFO Sells $12,000.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares in the company, valued at approximately $336,690. This represents a 3.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00.

Capricor Therapeutics Stock Down 13.0%

Shares of NASDAQ CAPR opened at $26.44 on Friday. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The firm has a market cap of $1.53 billion, a P/E ratio of -11.40 and a beta of 0.39. The company has a 50 day moving average of $30.00 and a 200 day moving average of $28.41.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts expect that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CAPR. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. B. Riley Financial upped their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $38.00 price target on shares of Capricor Therapeutics in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $50.30.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after buying an additional 355,161 shares during the period. Suvretta Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter worth $51,533,000. Tang Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter worth $49,062,000. RA Capital Management L.P. bought a new stake in shares of Capricor Therapeutics in the fourth quarter worth $43,516,000. Finally, Geode Capital Management LLC increased its position in Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock valued at $29,367,000 after acquiring an additional 55,766 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.